[en] [en] BACKGROUND: Urolithin A (UA) and urolithin B (UB) are gut microbiota-derived metabolites of ellagitannins reported to influence mitochondrial function, inflammation and muscle metabolism. Their comparative transcriptomic effects in human skeletal muscle cells remain undefined. We characterized UA- and UB-induced molecular responses in primary human myotubes.
METHODS: Primary CD56+ satellite cells were isolated from vastus lateralis muscle of 9 donors (6 men, 3 women; age 55-96 years; mean 74.1 ± 13.8 years) and differentiated into myotubes. Cells were treated 24 h with UA or UB (5 μM). RNA sequencing generated ~20 million paired-end reads per sample. Differential expression analysis was performed using DESeq2 (design = ~Patient + Treatment). Differentially expressed genes were defined as adjusted p value (FDR) < 0.01 and |Log2FoldChange| > 0.32. Pathway enrichment was assessed using Ingenuity Pathway Analysis. Selected targets were validated by RT-qPCR and ELISA in 4 donors from the RNA-seq cohort using UA and UB at 1, 5 and 10 μM.
RESULTS: UA and UB significantly modulated 1918 and 339 genes, respectively (FDR < 0.01; |log2FoldChange| > 0.32), demonstrating distinct transcriptomic reprogramming in human myotubes. Pathway analysis showed that UA predominantly affected oxidative phosphorylation, mitochondrial dysfunction, inositol phosphate metabolism and glycosylation pathways (N-linked glycosylation z score 2.11), whereas UB activated cholesterol biosynthesis (z score 2.45), mevalonate pathway (z score 2.00), adipogenesis (z score 1.41) and inhibited eicosanoid signalling (z score -2.71). At 5 μM (RNA-seq), UA increased NOTCH1 (+73%), MYMX (+70%), PANX1 (+50%) and MSTN (+64%), and decreased FGF9 (-75%), ICAM5 (-52%) and MRLN (-33%), whereas UB decreased IGFN1 (-75%), TGFBI (-60%) and STC2 (-35%) and increased TGM2 (+59%). UA increased LIF (+80%) and decreased PTGS1 (-41%) and IL17B (-49%), whereas UB decreased PTGS1 (-43%) and increased IL17B (+45%). RT-qPCR validation confirmed UA-induced increases in NOTCH1 (5 μM, p = 0.0471), MYMX (10 μM, p = 0.0363), and PANX1 (5 μM, p = 0.0012; 10 μM, p = 0.0065), dose-dependent reductions in FGF9 (r2 = 0.9389) and ICAM5 (r2 = 0.8804), and opposite regulation of IL17B (UA r2 = 0.8309; UB 10 μM, p = 0.0498) and PTGS1. Both UA and UB reduced TGFBI protein levels dose-dependently (UA r2 = 0.8582; UB r2 = 0.7415).
CONCLUSIONS: UA and UB induce quantitatively and qualitatively distinct transcriptomic programmes in human myotubes. UA preferentially modulates mitochondrial and inflammatory pathways, whereas UB primarily affects lipid metabolism and muscle-related processes. These findings provide mechanistic insight into urolithin-mediated regulation of human muscle cell biology able Stro.
Research Center/Unit :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > Pathologie générale et physiopathologie - Techniques particulières de kinésithérapie ; Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium
Florin, Antoine ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > musculoSkeletal Innovative research Lab (mSKIL)
Sanchez, Christelle ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > musculoSkeletal Innovative research Lab (mSKIL)
Centonze, Prescilia ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > musculoSkeletal Innovative research Lab (mSKIL)
Pinto Coelho, Tiago ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie ; Université de Liège - ULiège > GIGA > GIGA Metabolism & Cardiovascular Biology - Translational Research in Nephrology
Bekisz, Sophie ; Université de Liège - ULiège > GIGA > GIGA Molecular & Computational Biology - Biomechanics Research Unit
Dubuc, Jean-Emile; Orthopaedic Department, University Clinics St Luc, Brussels, Belgium
Galand, Olivier; Orthopaedic Department, Bois de l'Abbaye Hospital, Seraing, Belgium
Lambert, Cécile ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > musculoSkeletal Innovative research Lab (mSKIL)
Language :
English
Title :
Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes.
I. H. Rosenberg, “Sarcopenia: Origins and Clinical Relevance,” Journal of Nutrition 127 (1997): 990S–991S.
A. J. Cruz-Jentoft, G. Bahat, J. Bauer, et al., “Sarcopenia: Revised European Consensus on Definition and Diagnosis,” Age and Ageing 48 (2019): 16–31.
L. Cao and J. E. Morley, “Sarcopenia Is Recognized as an Independent Condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code,” Journal of the American Medical Directors Association 17 (2016): 675–677.
A. J. Cruz-Jentoft, F. Landi, S. M. Schneider, et al., “Prevalence of and Interventions for Sarcopenia in Ageing Adults: A Systematic Review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS),” Age and Ageing 43 (2014): 48–759.
A. J. Cruz-Jentoft, J. P. Baeyens, J. M. Bauer, et al., “Sarcopenia: European Consensus on Definition and Diagnosis: Report of the European Working Group on Sarcopenia in Older People,” Age and Ageing 39 (2010): 412–423.
E. Dent, J. E. Morley, A. J. Cruz-Jentoft, et al., “International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management,” Journal of Nutrition, Health & Aging 22 (2018): 1148–1161.
S. M. Robinson, J. Y. Reginster, R. Rizzoli, et al., “Does Nutrition Play a Role in the Prevention and Management of Sarcopenia?,” Clinical Nutrition 37 (2018): 1121–1132.
D. A. Papanicolaou, S. N. Ather, H. Zhu, et al., “A Phase IIA Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Selective Androgen Receptor Modulator (SARM), MK-0773 in Female Participants With Sarcopenia,” Journal of Nutrition, Health & Aging 17 (2013): 533–543.
J. T. Dalton, K. G. Barnette, C. E. Bohl, et al., “The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial,” Journal of Cachexia, Sarcopenia and Muscle 2 (2011): 153–161.
C. Becker, S. R. Lord, S. A. Studenski, et al., “Myostatin Antibody (LY2495655) in Older Weak Fallers: A Proof-of-Concept, Randomised, Phase 2 Trial,” Lancet Diabetes and Endocrinology 3 (2015): 948–957.
D. Rooks, J. Praestgaard, S. Hariry, et al., “Treatment of Sarcopenia With Bimagrumab: Results From a Phase II, Randomized, Controlled, Proof-of-Concept Study,” Journal of the American Geriatrics Society 65 (2017): 1988–1995.
R. García-Villalba, J. A. Giménez-Bastida, A. Cortés-Martín, et al., “Urolithins: A Comprehensive Update on Their Metabolism, Bioactivity, and Associated Gut Microbiota,” Molecular Nutrition & Food Research 66 (2022): e2101019.
L. An, Q. Lu, K. Wang, and Y. Wang, “Urolithins: A Prospective Alternative Against Brain Aging,” Nutrients 15 (2023): 3884.
F. A. Tomás-Barberán, A. González-Sarrías, R. García-Villalba, et al., “Urolithins, the Rescue of ‘Old’ Metabolites to Understand a ‘New’ Concept: Metabotypes as a Nexus Among Phenolic Metabolism, Microbiota Dysbiosis, and Host Health Status,” Molecular Nutrition & Food Research 61 (2017): 1500901.
A. Cortés-Martín, M. V. Selma, F. A. Tomás-Barberán, A. González-Sarrías, and J. C. Espín, “Where to Look Into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated With Human Metabotypes,” Molecular Nutrition & Food Research 64 (2020): e1900952.
P. A. Andreux, W. Blanco-Bose, D. Ryu, et al., “The Mitophagy Activator Urolithin A Is Safe and Induces a Molecular Signature of Improved Mitochondrial and Cellular Health in Humans,” Nature Metabolism 1 (2019): 595–603.
A. Singh, D. D'Amico, P. A. Andreux, et al., “Urolithin A Improves Muscle Strength, Exercise Performance, and Biomarkers of Mitochondrial Health in a Randomized Trial in Middle-Aged Adults,” Cell Reports Medicine 3 (2022): 100633.
J. Rodriguez, N. Pierre, D. Naslain, et al., “Urolithin B, a Newly Identified Regulator of Skeletal Muscle Mass,” Journal of Cachexia, Sarcopenia and Muscle 8 (2017): 583–597.
M. Francaux and L. Deldicque, “Using Polyphenol Derivatives to Prevent Muscle Wasting,” Current Opinion in Clinical Nutrition and Metabolic Care 21 (2018): 159–163.
P. Luan, D. D'Amico, P. A. Andreux, et al., “Urolithin A Improves Muscle Function by Inducing Mitophagy in Muscular Dystrophy,” Science Translational Medicine 13 (2021): eabb0319.
A. Singh, D. D'Amico, P. A. Andreux, et al., “Direct Supplementation With Urolithin A Overcomes Limitations of Dietary Exposure and Gut Microbiome Variability in Healthy Adults to Achieve Consistent Levels Across the Population,” European Journal of Clinical Nutrition 76 (2022): 297–308.
C. Labarca and K. Paigen, “A Simple, Rapid, and Sensitive DNA Assay Procedure,” Analytical Biochemistry 102 (1980): 344–352.
Y. Rolland, C. Dray, B. Vellas, and P. D. S. Barreto, “Current and Investigational Medications for the Treatment of Sarcopenia,” Metabolism 149 (2023): 155597.
H. Zhao, G. Song, H. Zhu, et al., “Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects,” Nutrients 15 (2023): 15.
X. Huang, H. Gao, X. Jiang, and Z. Zheng, “Urolithin B, a Gut Microbiota Metabolite, Reduced Susceptibility to Myocardial Arrhythmic Predisposition After Hypoxia,” Disease Markers 2022 (2022): 5313554.
J. Djedjibegovic, A. Marjanovic, E. Panieri, and L. Saso, “Ellagic Acid-Derived Urolithins as Modulators of Oxidative Stress,” Oxidative Medicine and Cellular Longevity 2020 (2020): 5194508.
C. Liu, Z. Xie, Q. Yuan, et al., “Interleukin-17B Is a New Biomarker of Human Muscle Regeneration in Dystrophinopathies,” Brain 148 (2025): 2579–2591.
L. Pan, W. Xie, X. Fu, et al., “Inflammation and Sarcopenia: A Focus on Circulating Inflammatory Cytokines,” Experimental Gerontology 154 (2021): 111544.
D. Ross and D. Siegel, “The Diverse Functionality of NQO1 and Its Roles in Redox Control,” Redox Biology 41 (2021): 101950.
B. Tu-sekine and S. F. Kim, “The Inositol Phosphate System—A Coordinator of Metabolic Adaptability,” International Journal of Molecular Sciences 23 (2022): 6747.
J. Faitg, D. D'Amico, C. Rinsch, and A. Singh, “Mitophagy Activation by Urolithin A to Target Muscle Aging,” Calcified Tissue International 114 (2024): 53–59.
K. Dang, S. Jiang, Y. Gao, and A. Qian, “The Role of Protein Glycosylation in Muscle Diseases,” Molecular Biology Reports 49 (2022): 8037–8049.
S. Dalle, L. Rossmeislova, and K. Koppo, “The Role of Inflammation in Age-Related Sarcopenia,” Frontiers in Physiology 8 (2017): 1045.
S. E. Riechman, C. W. Lee, G. Chikani, V. C. W. Chen, and T. V. Lee, “Cholesterol and Skeletal Muscle Health,” World Review of Nutrition and Dietetics 100 (2009): 71–79.
W. Chen, W. You, T. G. Valencak, and T. Shan, “Bidirectional Roles of Skeletal Muscle Fibro-Adipogenic Progenitors in Homeostasis and Disease,” Ageing Research Reviews 80 (2022): 101682.
Y. Zhang, Y. Jo, S. Wei, et al., “Myosteatosis: Epidemiological Insights, Functional Decline, and Diagnostic Advances,” Current Obesity Reports 14 (2025): 83.
A. S. Shams, R. W. Arpke, M. D. Gearhart, et al., “The Chemokine Receptor CXCR4 Regulates Satellite Cell Activation, Early Expansion, and Self-Renewal, in Response to Skeletal Muscle Injury,” Frontiers in Cell and Developmental Biology 10 (2022): 949532.
P. G. Ferreira, M. Muñoz-Aguirre, F. Reverter, et al., “The Effects of Death and Post-Mortem Cold Ischemia on Human Tissue Transcriptomes,” Nature Communications 9 (2018): 490.
M. Latil, P. Rocheteau, L. Châtre, et al., “Skeletal Muscle Stem Cells Adopt a Dormant Cell State Post Mortem and Retain Regenerative Capacity,” Nature Communications 3 (2012): 903.
T. Pietrangelo, R. Demontis, C. Santangelo, et al., “New Perspectives for Postmortem Human Satellite Cells of Different Embryological Origin,” Frontiers in Physiology 13 (2022): 886149.
